Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

Core Viewpoint - The domestic vaccine industry is facing significant pressure in 2024, with Kangtai Biological's performance showing volatility, including a substantial decline in revenue and net profit throughout the year [1] Group 1: Financial Performance - Kangtai Biological's total revenue and net profit for the year were 2.652 billion yuan and 202 million yuan, representing declines of 23.75% and 76.59% year-on-year, respectively [1] - In the first quarter of 2024, the company managed to halt the revenue decline, but net profit still plummeted by 58.51% to 22.4341 million yuan [1] - The company's stock price has dropped over 48% year-to-date [1] Group 2: Vaccine Product Performance - The company's immune planning vaccines showed a mixed performance, with the hepatitis B vaccine's batch issuance increasing by 38.60% to 10.188 million doses, while the whooping cough vaccine saw a dramatic decline of 72.28% to 623,100 doses [2] - Despite a 144.07% increase in revenue from immune planning vaccines, this segment only contributed 2.3% to the total revenue [2] - Non-immune planning vaccines, which are a core revenue source, saw a 26.02% decline in revenue to 2.546 billion yuan, despite significant increases in batch issuance for several products [3] Group 3: Market Dynamics and Competition - The immune planning vaccines are generally procured by the government at lower prices, resulting in limited profit margins, while non-immune planning vaccines have a much higher gross margin of 84.30% compared to 25.24% for immune planning vaccines [3] - The market for the 13-valent pneumonia vaccine is becoming increasingly competitive, with Kangtai Biological facing challenges from established players like Pfizer and Watson Biotech [6] - The company has a pipeline of nearly 30 products in development, but past experiences indicate that having a robust pipeline does not guarantee significant revenue growth [7] Group 4: Financial Health and Risks - As of the end of the first quarter, Kangtai Biological's accounts receivable reached 2.854 billion yuan, a year-on-year increase of 5.1%, with a high inventory turnover period of 396.48 days [9] - The company has made provisions for credit impairment and asset impairment totaling 260 million yuan, indicating potential financial risks [10]

Group 1 - The core point of the news is that Dize Pharmaceutical is the first unprofitable company on the Shanghai Stock Exchange to receive registration for refinancing since the release of the "Kebatiaos" policy [1][2] - Dize Pharmaceutical completed a private placement of 1.796 billion yuan, with a share price set at 43.00 yuan per share, involving 24 subscription participants, including public funds and foreign institutional investors [1] - The purpose of the refinancing is to invest in new drug research and development, international standard innovative drug industrialization projects, and to supplement working capital [1] Group 2 - Dize Pharmaceutical has two products, Shuwozhe and Gaoruizhe, that have been launched in China and included in the new national medical insurance catalog, with Shuwozhe's application to the FDA accepted for priority review [1] - The company reported a net loss of 857 million yuan for 2024, which is a reduction of 251 million yuan compared to the previous year [1] - The capital market for biopharmaceuticals is showing signs of recovery, with over half of the 110 stocks in the Sci-Tech Innovation Board's biopharmaceutical sector having positive cumulative returns this year [2]

Core Viewpoint - In the post-COVID era, CanSino's performance is showing signs of recovery, primarily driven by the sales of its meningococcal vaccines, despite the overall market challenges for meningitis vaccines in China [3][4]. Financial Performance - CanSino reported a revenue of 846 million yuan for 2024, marking a year-on-year increase of 137.01% [3]. - The company achieved a net loss attributable to shareholders of 379 million yuan, which is a 74.45% reduction in losses compared to the previous year [3]. - The adjusted net loss was 441 million yuan, reflecting a 72.61% decrease in losses year-on-year [3]. Vaccine Sales and Market Position - The two meningococcal vaccines generated approximately 794 million yuan in sales, representing a year-on-year growth of 41.31% [3]. - CanSino's four-valent meningococcal vaccine, "Manhaixin," is the first in China and the third globally approved for infants under six months, filling a significant market gap [4]. - Despite having a leading position in the four-valent meningococcal vaccine market, CanSino's overall market share remains low compared to other vaccines [4]. Market Dynamics - The demand for meningitis vaccines is influenced by the low incidence rate of the disease in China, which is approximately 0.2 cases per 100,000 people, with around 100 cases reported annually [5]. - The popularity of free Class I vaccines, which are more accessible to economically disadvantaged families, poses a challenge for the uptake of CanSino's vaccines [4][5]. Expansion Strategies - CanSino plans to expand the age range for its four-valent meningococcal vaccine to include children up to six years old and is preparing for clinical trials for ages 7 to 59 [6]. - The company is targeting international markets, particularly in Southeast Asia, the Middle East, North Africa, and South America, with successful registration in Indonesia and obtaining Halal certification [6][7]. - CanSino's strategy includes forming local partnerships to facilitate product registration and market promotion in foreign countries [7]. Future Prospects - CanSino is also close to launching its 13-valent pneumococcal conjugate vaccine (PCV13i), which has a broader market potential compared to meningococcal vaccines [7].

《香港联合交易所有限公司证券上市规则》等相关规定，康希诺生物股份公司（以 下简称"康希诺"或"公司"）于2025年3月25日召开第三届董事会第六次会议， 审议通过《关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 案》，同意公司董事会提请股东大会授权董事会决定公司向特定对象发行融资总 额不超过人民币3亿元且不超过最近一年末净资产20%的股票，授权期限为自公 司2024年年度股东大会审议通过之日起至公司2025年年度股东大会召开之日止。 康希诺: 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 证券代码：688185 证券简称：康希诺 公告编号：2025-009 康希诺生物股份公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》及 本议案尚需提交公司2024年年度股东大会审议通过 ...

康希诺: 2024年度环境、社会及管治（ESG）报告暨可持续发 展报告 关于本报告 本期环境、社会及管治（ESG）暨可持续发展报告本着客观、规范、透明和全面的原则，详细披露了康希诺生物在经营与发 展、环境、劳工与社区、价值链等领域内的 ESG 与可持续发 展的社会责任实践和绩效。 编制依据 汇报原则 本报告依照香港联合交易所有限公司《香港联合交易所有限公司证券上市规则》附录 C2《环 重要性： 为编制本报告，本公司开展议题重要性评估程序，以确定本报告的披露内容及各 境、社会及管治报告守则》及上海证券交易所《上海证券交易所上市公司环境信息披露指 议题内容的 详实程度。2024 年度重大性议题分析结果已呈列在"利益相关方沟通"小节中。 引》要求，参考上海证券交易所《上市公司自律监管指引 第 14 号——可持续发展报告（试 量化：本报告在环境、社会范畴均披露定量数据以展现 我们在各关键 ESG 绩效指标中的 行）》，并参照全球可持续发展标准委员会 (GSSB) 发布的《GRI 可持续发展报告标准》 （GRI 表现。 Standards）要求编写。 报告范围 平衡：本报告客观披露正面及负面信息，确保内容平 衡。 一致 ...

目 录 委托单位： 审计单位： 康希诺: 控股股东、实际控制人及其他关联方资金占 用情况的专项说明 关于康希诺生物股份公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 联系电话： 限公司 总计 3,232.44 49,783.70 64.42 38,172.30 14,908.26 注：该金额已全额计提预期信用损失。 | | | 占用方 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 与上市 | 上市公司 | 2024 年期 | | | 2024 年度 | 2024 | | 年期 | | | | | | | | | | 非经营性资金占 | | 资金占用方 | | | | 占用累计发 | 占用资 | | | 金 | | | 占用形 | | | | | | | | | 公司的 | 核算的会 | 初占用资金 | | | 偿还累计 | | | 发 | 末占用资金 | | 占用性质 | | | | | | | 用 | 名称 | | | | 生金额(不 | 的利 | | | | 息 | | | 成原因 ...

Core Viewpoint - The company has developed a "Quality Improvement and Efficiency Enhancement Return to Shareholders" action plan for 2025, aiming to enhance operational efficiency, strengthen market competitiveness, and improve its image in the capital market [1] Group 1: Business Focus and Innovation - The company focuses on its core business of developing, producing, and commercializing innovative vaccines that meet both Chinese and international standards, achieving a revenue of approximately 793.79 million yuan, a 41.31% increase year-on-year [1] - The company plans to continue promoting its unique quadrivalent meningococcal vaccine, MCV4, and has submitted an application to expand its age coverage, which, once approved, will enhance its market presence [1] - The company is also preparing for the commercialization of its product PCV13i, having completed clinical site inspections and is actively engaging with regulatory authorities to ensure smooth approval processes [2] Group 2: International Strategy and Market Expansion - The company's international strategy is based on a "full value chain layout," establishing local production bases in countries like Pakistan, Mexico, and Malaysia to meet public health needs [3] - The company aims to explore the feasibility of product procurement by international organizations and is preparing for WHO PQ certification to enhance its global market access [3] Group 3: Corporate Governance and Shareholder Returns - The company is committed to improving corporate governance and internal control systems to ensure compliance and protect shareholder rights [4] - A three-year shareholder dividend plan has been established, with cash dividends amounting to approximately 198 million yuan since its listing, and a share buyback of 683,748 shares, representing about 0.2763% of total shares [5] Group 4: Investor Relations and Communication - The company actively engages with investors through various channels, including performance briefings and investor open days, to communicate its operational and financial status [6] - The first investor open day was held in November 2024, where management shared insights on vaccine development and future strategies [6] Group 5: ESG Commitment - The company plans to enhance its ESG performance and reporting in line with regulatory requirements, aiming to address stakeholder expectations regarding sustainability [6] Group 6: Responsibility and Compliance - The company emphasizes the importance of compliance among its key personnel and has organized training to enhance their understanding of regulations and responsibilities [7] - Continuous evaluation of the action plan will be conducted to ensure focus on core competencies and risk management [7]

康希诺: 2024年度内部控制评价报告 公司代码：688185 公司简称：康希诺 康希诺生物股份公司 康希诺生物股份公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评 价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致 ...

Core Viewpoint - The company plans to utilize up to RMB 2.8 billion of its temporarily idle funds for cash management, aiming to enhance fund efficiency and increase returns while ensuring that its main business operations remain unaffected [1][2]. Group 1: Overview of Cash Management - The purpose of cash management is to improve fund utilization efficiency and increase company revenue while ensuring sufficient liquidity for normal operations [2]. - The source of funds for this cash management initiative will be the company's temporarily idle self-owned funds, which will not impact normal business operations [2]. - The maximum daily balance for cash management is set at RMB 2.8 billion, with the ability to roll over funds within this limit [2]. - The authorization period for this initiative is 12 months from the date of board approval, with the chairman authorized to make investment decisions [2]. - The company will adhere to prudent investment principles, selecting high-security, liquid, and low-risk investment products [2]. Group 2: Impact on the Company - Utilizing idle self-owned funds for cash management is expected to enhance fund efficiency and increase returns for the company and its shareholders, without significantly impacting future main business operations, financial status, operating results, or cash flow [2]. Group 3: Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on March 25, 2025, confirming compliance with relevant regulations and ensuring that shareholder interests, especially those of minority shareholders, are protected [4].